Inseco’s closure this week is a quiet, instructive end to what was once one of South Africa’s most promising cleantech bets.
The Cape Town insect-protein pioneer, which raised a headline-grabbing $5.3 million seed round in 2022, has folded after almost seven years and quietly sold its equipment and some intellectual property to industry partners.
The story is less about a single startup failing and more about the tightrope that hardware-first, biological manufacturing plays in markets that still lack dependable industrial infrastructure.
At its core, Inseco built a simple circular thesis: convert organic processing waste into black soldier fly larvae, then process the larvae into protein meal, oil and fertiliser for aquaculture, pet food and poultry.
Early accolades and awards suggested the model could translate to scale. But execution risk, financing cadence and local operating realities collided.
The most immediate, measurable blow came from South Africa’s chronic power shortages. Repeated multi-hour outages forced temperature-sensitive insect colonies into unstable conditions, pushed energy costs up sharply and interrupted processing lines that rely on continuous power. Inseco had budgeted for a large backup generator but delayed that purchase to conserve cash.
That tradeoff, which founders later called a mistake, transformed an operational nuisance into an existential problem: missed production windows, stranded offtake contracts priced in dollars and euros, talent attrition, and a loss of investor momentum.
Founders are candid in their post-mortem: loadshedding was a major factor, but not the only one. Rapid scaling decisions, hires that did not fit execution needs, and slow progress on margin-improving technology all contributed.
The company pursued a scale point that assumed price declines at volume; when scale proved harder and more costly than modelled, the assumed economics did not materialise in time.
Inseco’s experience echoes pressures felt by peers in insect agriculture globally. Industry names in Europe and the US have also struggled to translate pilot promise into profitable, commodity-scale production.
The technology works, but getting to price parity with fishmeal, soy and other entrenched feed ingredients requires relentless cost discipline, optimized processing, local supply certainty and, often, access to low-cost, reliable energy.
There are wider lessons here for founders, investors and policymakers. For founders building hardware- and biologics-heavy ventures in emerging markets, contingency capital for predictable infrastructure risks should be non-negotiable.
That means budgeting and contracting for backup power, redundancy in critical systems and staged expansion plans that validate unit economics before adding capacity. Investors, for their part, should demand more conservative stress testing of operating models that hinge on grid stability or foreign-denominated offtake.
Term sheets and monitoring could explicitly include milestones tied to resilience investments.
Policymakers also have a role. Industrial-scale biological manufacturing depends on reliable, affordable electricity. Where national grids are fragile, targeted incentives or concessional financing for resilience infrastructure could materially change the investment calculus.
The sale of Inseco’s assets into the market and the company’s remaining IP being repurposed by partners suggests a period of consolidation and consolidation-driven learning that could lower barriers for the next cohort of entrants.
Finally, a word on sector outlook. Current global volumes for insect protein remain small today, but several market studies project meaningful growth over the next five years.
Achieving that growth will require the industry to move from pilot subsidies and venture optimism into engineering for cost, service-level agreements with buyers, and a playbook that balances scale with operational durability.
Inseco’s founders say they still believe in the technology; their failure is a reminder that credible engineering and reliable infrastructure are as important as the science.
For investors and founders chasing sustainable agrifood alternatives in Africa, the Inseco file should be read not as a warning to walk away but as a blueprint of what to ask for before writing the next cheque.
Don’t miss important articles during the week. Subscribe to techbuild weekly digest for updates
